生物药物开发用于治疗和预防性传播感染
Davinder S Gill1, Sanjay Ram2, Peter A Rice2
1StiRx Inc, Mansfield, Massachusetts, USA.
Clinical microbiology reviews
|May 29, 2025
概括
创新的生物药物对于对抗抗生素耐药性性传播感染 (STIs) 的增加至关重要. 这篇评论探讨了疫苗,抗体和性传播感染的新疗法,如克拉米迪亚和淋病.
科学领域:
- 传染病和免疫学 传染病和免疫学
- 药物开发和药理学 药物开发和药理学
背景情况:
- 性传播感染 (STIs) 构成了全球重大健康挑战,每天有超过100万例新感染.
- 性传播感染中抗生素耐药性增加加剧了诸如不孕不育和艾滋病毒风险增加等并发症,需要新的治疗和预防策略.
研究的目的:
- 提供对主要性传播感染的生物药物开发的综合分析,包括克拉米迪亚性传播感染,尼塞利亚淋病,HSV-2和Treponema pallidum.
- 研究宿主-病原体相互作用,粘膜免疫以及用于创新的STI管理的新兴技术.
主要方法:
- 审查目前针对性传播感染的生物药物开发.
- 对宿主-病原体相互作用,免疫逃避和潜伏的分析.
- 对治疗平台的调查,包括疫苗,单克隆抗体,蛋白质疗法,基于核酸的疗法,微生物组调制和菌体干预.
主要成果:
- 对性病的生物药物开发面临由于病原体机制和免疫逃避的复杂性.
- 粘膜免疫,居住记忆T细胞和细胞因子反应方面的进展正在指导治疗向.
- 有望的疫苗研发已被指出,用于克拉米迪亚甲状腺炎和尼塞里亚淋病.
结论:
- 利用抗原保护,宿主免疫调节和新型传递平台的综合战略对于有效的STI预防和治疗至关重要.
- 解决STI管理中的未满足需求需要在既定和新兴的生物治疗方法中进行创新.
- 生物疗法在全球范围内提供了对抗高负担性传播感染的巨大潜力.
关键词:
克拉米迪亚菌落状虫病 (chlamydia trachomatis) 是一种感染性疾病.尼塞里亚淋病菌 (Neisseria gonorrhoeae) 是一种传染病.它们中的一个是Treponema pallidum.抗微生物是一种抗微生物.克拉米迪亚病毒是什么淋病 Gonorrhea 这是一种淋病.简单疹病毒 (HSV) 病毒微生物组是一个微生物组.这是一种单克隆抗体.菌体 菌体是一种菌体.菌体疗法是一种菌体疗法.梅毒是什么 梅毒是什么 梅毒是什么疫苗 疫苗 疫苗 疫苗更多相关视频
相关概念视频
01:26Sexually Transmitted Infections
941
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
941
01:28Drug Products: Biologics, Biosimilars and Interchangeables
235
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
235
01:29Microorganisms in Medicine and Therapeutics
989
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
989
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
506
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
506
01:11Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
01:28Preclinical Development: Overview
5.9K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.9K